NRG1 fusion-positive solid tumors: clinical detection, genomic landscape, and real-world data in PDAC [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; ...

With current CDC leadership waiting for Senate confirmation, the Advisory Committee's vaccination recommendations may be approved by Health Secretary Robert F. Kennedy Jr instead. HealthDay News ...

“The preclinical and non-human primate studies suggest RB-164™ has the potential to translate into meaningful clinical benefits with acceptable toxicity for patients with ROR-1 positive hematologic ...

Our group's aim is to improve the treatment and survival of children with neuroblastoma, medulloblastoma and rhabdomyosarcoma. The goal of our laboratory is to improve the treatment and survival of ...

See reviews below to learn more or submit your own review. Gillette has been producing shaving products and personal care items since 1901. Its offerings include razors, blades and grooming ...

Subjects with locally advanced or metastatic solid tumours, including high-grade serious ovarian cancer, are being enrolled in the trial. The start of the trial comes after Accent’s first asset, ...

We assessed the safety, maximum tolerated dose, and recommended phase 2 dose (RP2D), efficacy, pharmacokinetics, and pharmacodynamics of the nilotinib–paclitaxel combination in 44 patients with solid ...

of RB-164™ in participants with hematologic cancers such as lymphoma and advanced solid tumors that are associated with high ROR-1 expression. The Phase 1 clinical trial initiates with dose ...

today announced that the first patient has been treated in its Phase 1 clinical trial evaluating PHST001, an anti-CD24 macrophage checkpoint inhibitor, in patients with advanced solid tumors. “The ...